Laurus Labs Current Share Price | Laurus Labs Stock Screener
LAURUSLABS
Pharmaceuticals
Laurus Labs Current Stock Price Today
Live Share Price NSE
₹1954.00
▲
5.90 (0.30%)
Live Share Price BSE
₹1955.25
▼
-1.15 (-0.06%)
As of September 18, 2026, the live Laurus Labs share price (NSE: LAURUSLABS) is ₹1,954.00 on NSE and ₹1,955.25 on BSE, up 0.30% from the previous close, with shares trading between ₹1,954.00 and ₹1,982.00 in today's trading session, and a 52-week range of ₹832.30–₹1,969.00.
Browse LAURUSLABS balance sheet details to support your investment research.
Use the Laurus Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Laurus Labs Market Cap
₹103,852.21 Cr.
LAURUSLABS P/E Ratio (TTM)
97.64
Laurus Labs P/B Ratio
19.74
EPS (TTM)
₹16.47
Dividend Yield
0.10%
Debt to Equity
0.54
LAURUSLABS 52 Week High
₹1969.00
Laurus Labs 52 Week Low
₹832.30
Operating Margin
28.00%
Profit Margin
15.47%
LAURUSLABS Revenue (TTM)
₹1,823.00
EBITDA
₹524.00
Net Income
₹282.00
Total Assets
₹10,511.00
Total Equity
₹5,431.00
Laurus Labs Current Share Price Chart
Track the current Laurus Labs share price and stock price with an interactive chart. Analyse LAURUSLABS price trends, trading volume, historical performance, and volatility across different timeframes — the complete Laurus Labs stock quote in one place.
Laurus Labs Company Profile - Fundamental Screener
Screen Laurus Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for LAURUSLABS shares.
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Ravindranath Kancherla
ISIN
INE947Q01028
Website
https://www.lauruslabs.com
Laurus Labs Balance Sheet Screener
Screen LAURUSLABS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 10,511 | 9,336 | 8,387 | 7,660 | 6,968 | 5,751 | 3,750 | 3,331 | 3,017 | 2,653 |
| Current Assets | 4,829 | 4,332 | 3,835 | 3,462 | 3,345 | 3,075 | 1,812 | 1,463 | 1,248 | 1,140 |
| Fixed Assets | 4,371 | 4,123 | 3,890 | 3,409 | 2,653 | 2,171 | 1,726 | 1,629 | 1,481 | 1,230 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,444 | 1,193 | 1,159 | 1,180 | 928 | 693 | 288 | 349 | 227 | 202 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 5,431 | 4,603 | 4,116 | 4,049 | 3,359 | 2,601 | 1,770 | 1,558 | 1,483 | 1,330 |
| Share Capital | 108 | 108 | 108 | 108 | 108 | 107 | 107 | 106 | 106 | 106 |
| Reserves & Surplus | 5,192 | 4,365 | 4,003 | 3,930 | 3,244 | 2,490 | 1,658 | 1,447 | 1,371 | 1,225 |
Laurus Labs Income Statement Screener - Profit & Revenue Analysis
Screen Laurus Labs income statement and profit fundamentals.
Analyze LAURUSLABS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Laurus Labs share price evaluation.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,823 | 2,036 | 1,779 | 1,580 | 1,680 | 1,784 | 1,458 | 1,197 | 1,228 | 1,425 | 1,383 | 1,185 | 1,226 | 1,197 | 1,426 |
| Expenses | 1,300 | 1,388 | 1,300 | 1,187 | 1,250 | 1,298 | 1,198 | 1,024 | 1,045 | 1,130 | 1,095 | 1,015 | 1,037 | 1,014 | 1,028 |
| EBITDA | 524 | 648 | 479 | 393 | 430 | 486 | 260 | 174 | 183 | 295 | 287 | 170 | 190 | 184 | 398 |
| Operating Profit % | 28.00% | 32.00% | 24.00% | 24.00% | 24.00% | 27.00% | 17.00% | 14.00% | 15.00% | 20.00% | 21.00% | 14.00% | 15.00% | 15.00% | 28.00% |
| Depreciation | 122 | 124 | 110 | 117 | 121 | 121 | 102 | 106 | 108 | 106 | 87 | 91 | 93 | 98 | 66 |
| Interest | 40 | 42 | 56 | 52 | 40 | 39 | 51 | 49 | 53 | 58 | 53 | 39 | 42 | 51 | 31 |
| Profit Before Tax | 361 | 481 | 312 | 224 | 270 | 327 | 107 | 19 | 23 | 131 | 147 | 41 | 54 | 35 | 302 |
| Tax | 79 | 119 | 80 | 63 | 75 | 75 | 32 | 6 | 3 | 38 | 42 | 14 | 17 | 11 | 70 |
| Net Profit | 282 | 362 | 233 | 162 | 195 | 252 | 75 | 13 | 20 | 93 | 105 | 27 | 37 | 23 | 232 |
| EPS | 5.17 | 6.81 | 4.34 | 3.02 | 3.61 | 4.67 | 1.40 | 0.23 | 0.37 | 1.71 | 1.90 | 0.46 | 0.69 | 0.43 | 4.29 |
Laurus Labs Cash Flow Screener - Liquidity Fundamentals
Screen LAURUSLABS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,624 | 602 | 666 | 994 | 911 | 733 | 347 | 298 | 343 | 332 |
| Investing Activities | -1,086 | -680 | -822 | -997 | -915 | -941 | -221 | -253 | -384 | -289 |
| Financing Activities | -525 | 39 | 250 | -27 | 30 | 255 | -128 | -45 | 42 | -54 |
| Net Cash Flow | 13 | -39 | 93 | -30 | 27 | 47 | -1 | 0 | 1 | -10 |
Laurus Labs Shareholding Pattern Screener
See Laurus Labs shareholding pattern with promoter, FII, and DII holdings.
Check Laurus Labs promoter holding and ownership changes for LAURUSLABS on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 27.49% | 27.47% | 27.62% | 27.59% | 27.59% | 27.49% | 27.19% | 27.18% |
| FII Holding | 25.82% | 28.00% | 25.52% | 25.70% | 26.16% | 26.52% | 25.97% | 25.67% |
| DII Holding | 13.97% | 13.74% | 11.77% | 11.94% | 11.73% | 12.43% | 11.77% | 13.56% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 21.24% | 20.49% | 23.65% | 23.12% | 23.33% | 22.64% | 23.95% | 22.68% |
| Other Holding | 11.47% | 10.30% | 11.44% | 11.65% | 11.18% | 10.92% | 11.12% | 10.91% |
| Shareholder Count | 292,281 | 291,653 | 292,905 | 280,223 | 283,678 | 280,756 | 356,830 | 324,059 |
Laurus Labs Share Dividend Screener - Share Yield Analysis
Check Laurus Labs dividend history with payout and yield data.
View Laurus Labs dividend details including ex-dates and amounts for LAURUSLABS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹2.00 | 0.10% |
| 2025-March | ₹1.20 | 0.12% |
| 2024-March | ₹0.80 | 0.13% |
| 2023-March | ₹2.00 | 0.51% |
| 2022-March | ₹2.00 | 0.67% |
| 2021-March | ₹2.00 | 0.34% |
| 2020-March | ₹2.50 | 0.69% |
| 2019-March | ₹1.50 | 2.31% |
| 2018-March | ₹1.50 | 1.88% |
| 2017-March | ₹1.50 | 1.49% |
Laurus Labs Stock Index Membership
See which indices include Laurus Labs stock.
Check LAURUSLABS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEMOI
BSE INDEX MIDCAP
BSE INDEX MSL400
BSE INDEX SML250
NIFTY 500
NIFTY HEALTHCARE
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
Laurus Labs Market Events Screener - Corporate Actions
Get Laurus Labs corporate actions including splits, bonuses, and buybacks.
Check Laurus Labs stock events that may affect LAURUSLABS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-07-24 | 2026-07-24 | Quarterly Result Announcement | NA | 6.75% |
| 2026-07-02 | 2026-07-02 | Annual General Meeting | NA | 35.08% |
| 2026-05-08 | 2026-05-08 | Dividend | ₹ 1.20 /share | 9.12% |
| 2026-04-30 | 2026-04-30 | Quarterly Result Announcement | NA | 2.11% |
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -8.72% |
| 2025-10-31 | 2025-10-31 | Dividend | ₹ 0.80 /share | 5.03% |
| 2025-10-23 | 2025-10-23 | Quarterly Result Announcement | NA | 7.65% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | 7.48% |
| 2025-06-26 | 2025-06-26 | Annual General Meeting | NA | 10.52% |
| 2025-05-09 | 2025-05-09 | Dividend | ₹ 0.80 /share | -9.91% |
| 2025-04-24 | 2025-04-24 | Quarterly Result Announcement | NA | 15.28% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | -4.35% |
| 2024-11-06 | 2024-11-06 | Dividend | ₹ 0.40 /share | 8.88% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -6.44% |
| 2024-07-11 | 2024-07-11 | Annual General Meeting | NA | 8.77% |
Laurus Labs Competitors Screener - Peer Comparison
Screen LAURUSLABS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,958 | 36.48 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 244,032 | 84.64 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 184,497 | 87.77 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 110,937 | 24.32 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 109,479 | 32.86 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 103,852 | 97.64 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 95,611 | 30.44 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 94,811 | 25.98 | 34,145 | 5.56% | 3,503 | 57.04 |
| Mankind Pharma | 94,370 | 45.49 | 14,636 | 14.85% | 1,938 | 37.57 |
| Lupin | 93,865 | 17.27 | 29,039 | 26.75% | 5,356 | 28.17 |
Laurus Labs Company Announcements - News Screener
Screen LAURUSLABS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-08-10 | Intimation Of ESG Score Given By NSE Sustainability Ratings And Analytics Limited | - |
| 2026-07-30 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-07-27 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-07-25 | Update On Composite Scheme Of Arrangement | - |
| 2026-07-25 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-07-24 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-24 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-07-24 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-07-24 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-07-24 | Results - Financial Results For Quarter Ended 30.06.2026 | - |
| 2026-07-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-09 | Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-07-06 | Completion Of Tenure Of Independent Director | - |
| 2026-07-03 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-07-02 | Appointment Of Independent Directors At The 21St Annual General Meeting Of The Company | - |